A randomized waitlist-controlled design ( = 74) examined the efficacy of Reconsolidation of Traumatic Memories (RTM) among male veterans with current-month flashbacks and nightmares. Volunteers were randomly assigned to immediate treatment (three 120-minute sessions of RTM), or to a 3-week waiting condition before receiving the RTM treatment. Blinded psychometricians evaluated the symptoms at intake, 2 weeks, and 6 weeks post. Wait-listed participants were re-evaluated and then treated. Sixty-five volunteers completed the treatment. Of those treated, 46 (71%) lost DSM diagnosis for post-traumatic stress disorder (PTSD) by one of the following definitions: 42 persons (65%) were in complete remission (PTSD Symptom Scale Interview (PSS-I) ≤ 20 and DSM criteria not met). Four others (6%) lost the DSM diagnosis or were otherwise sub-clinical by dichotomous criteria (PSS-I < 20 and absence of flashbacks and nightmares) but non-ambiguous on the PTSD Checklist Military Version measures. Within-group RTM effect sizes (Hedges' ) for PSS-I score changes ranged from 1.45 to 2.3. The between-group comparison between the treatment group and the untreated controls was significant ( < .001) with an effect size equivalent to two standard deviations ( = 2.13; 95% CI [1.56, 2.70]). Patient satisfaction with the intervention was high. RTM shows promise as a brief, cost-effective intervention for PTSD characterized primarily by intrusive symptoms. The article provides evidence to support a fast (5 hours or fewer) robust intervention for PTSD characterized by intrusive symptoms including current-month flashbacks, nightmares, and accompanied by sympathetic arousal in response to trauma narratives. The intervention is well tolerated and has demonstrated efficacy up to one year.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/10503307.2017.1408973 | DOI Listing |
Transl Psychiatry
December 2024
School of Psychological Sciences, College of Health and Medicine, University of Tasmania, Tasmania, TAS, Australia.
This study establishes mirdametinib as the first MEK inhibitor that can undergo clinical development for psychiatric indications such as post-traumatic stress disorder (PTSD). PTSD is characterized by persistent traumatic memories with limited effective treatment options. A body of evidence suggests that memory storage is dynamic and constantly updated through post-retrieval modification a process termed reconsolidation.
View Article and Find Full Text PDFDrugs
November 2024
Department of Psychiatry and Behavioral Sciences, Center for Psychedelic Research and Therapy, The University of Texas at Austin Dell Medical School, 1601 Trinity Street, Bldg. B, Stop Z0600, Austin, TX, 78712, USA.
Posttraumatic stress disorder (PTSD) is a psychiatric disorder with defining abnormalities in memory, and psychedelics may be promising candidates for the treatment of PTSD given their effects on multiple memory systems. Most PTSD and psychedelic research has investigated memory with fear conditioning and extinction. While fruitful, conditioning and extinction provide a limited model of the complexity of PTSD and phenomenology of psychedelics, thereby limiting the refinement of therapies.
View Article and Find Full Text PDFCureus
September 2024
Society for Energy & Emotions, Wellness Space, Ahmedabad, IND.
This case study explores the memory reconsolidation-based technique of reconsolidation of traumatic memories (RTM) to address complex post-traumatic stress disorder (CPTSD). Using the framework of CPTSD and the components of International Trauma Questionnaire (ITQ), several presenting symptoms and the history of childhood trauma (adverse childhood experiences assessment) were assessed. The individual, based on the trauma-informed care approach, went through a total of eight sessions after the initial consultation that included RTM on index trauma events, reframing, and self-regulation techniques.
View Article and Find Full Text PDFBehav Brain Res
January 2025
School of Psychology, Shandong Second Medical University, 7166# Baotong West Street, Weifang, Shandong 261053, PR China. Electronic address:
Rationale: Fear memory, a fundamental symptom of post-traumatic stress disorder (PTSD), is improved by (2R, 6R)-hydroxynorketamine ((2R, 6R)-HNK) administration. However, the phase of fear memory in which the injected drug is the most effective at mitigating PTSD-like effects remains unknown.
Objective: This study aimed to explore the effects of (2 R, 6 R)-HNK administration during three phases [acquisition (AP), reconsolidation (RP), and extinction (EP)] on PTSD-like behaviors in single prolonged stress (SPS) and contextual fear conditioning (CFC) rat models.
Neurosci Biobehav Rev
December 2024
Department of Pharmacology, Federal University of Santa Catarina, Florianopolis, SC, Brazil. Electronic address:
Threatening events and stressful experiences can lead to maladaptive memories and related behaviors. Existing treatments often fail to address these issues linked to anxiety/stress-related disorders effectively. This review identifies dose ranges associated with specific actions across various psychedelics.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!